More evidence that the anticancer drug Avastin® may cause harm.

Printed from

A review of patients enrolled in 16 clinical trials has revealed that the antiangiogenesis drug bevacizumab (Avastin®) may actually increase the risk of death when combined with certain chemotherapy drugs. In combination with taxanes or platinum containing drugs, bevacizumab was associated with a significantly higher risk of death from treatment side-effects. The results indicate that the drug may have to be used with caution or not at all with these types of chemotherapy agents.

Source

http://jama.ama-assn.org/content/305/5/487.abstract Learn More Learn More